International Journal of Radiation Oncology * Biology * Physics
Volume 63, Issue 1 , Pages 5-24 , 1 September 2005

Radiation pneumonitis and pulmonary fibrosis in non–small-cell lung cancer: Pulmonary function, prediction, and prevention

  • Vivek Mehta, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Vivek Mehta, M.D., Department of Radiation Oncology, Swedish Cancer Institute, 1221 Madison St., Seattle, WA 98104. Tel: (206) 386-2323; Fax: (206) 363-5907

Received 6 December 2004 ,Revised 14 March 2005 ,Accepted 16 March 2005.

References 

  1. Pfister DG , Johnson DH , Azzoli CG , et al.   American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline (Update 2003) . J Clin Oncol . 2004;22:330–353
  2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology . J Clin Oncol . 1997;15:2996–3018
  3. Roach M , Gandara DR , Yuo HS , et al.   Radiation pneumonitis following combined modality therapy for lung cancer (Analysis of prognostic factors) . J Clin Oncol . 1995;13:2606–2612
  4. Senzer N . A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification (Preliminary findings) . Semin Oncol . 2002;29:38–41
  5. Leong SS , Tan EH , Fong KW , et al.   Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer . J Clin Oncol . 2003;21:1767–1774
  6. Magana E , Crowell RE . Radiation pneumonitis successfully treated with inhaled corticosteroids . South Med J . 2003;96:521–524
  7. Inoue A , Kunitoh H , Sekine I , et al.   Radiation pneumonitis in lung cancer patients (A retrospective study of risk factors and the long-term prognosis) . Int J Radiat Oncol Biol Phys . 2001;49:649–655
  8. Wang JY , Chen KY , Wang JT , et al.   Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis . Int J Radiat Oncol Biol Phys . 2002;54:735–741
  9. Ohe Y . Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer . Panminerva Med . 2002;44:205–212
  10. Movsas B , Raffin TA , Epstein AH , et al.   Pulmonary radiation injury . Chest . 1997;111:1061–1076
  11. Abid SH , Malhotra V , Perry MC . Radiation-induced and chemotherapy-induced pulmonary injury . Curr Opin Oncol . 2001;13:242–248
  12. Abratt RP , Morgan GW . Lung toxicity following chest irradiation in patients with lung cancer . Lung Cancer . 2002;35:103–109
  13. Werner-Wasik M , Yu X , Marks LB , et al.   Normal-tissue toxicities of thoracic radiation therapy (Esophagus, lung, and spinal cord as organs at risk) . Hematol Oncol Clin North Am . 2004;18:131–160 x-xi
  14. Fan M , Marks LB , Lind P , et al.   Relating radiation-induced regional lung injury to changes in pulmonary function tests . Int J Radiat Oncol Biol Phys . 2001;51:311–317
  15. Rubenstein JH , Richter MP , Moldofsky PJ , et al.   Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing . Int J Radiat Oncol Biol Phys . 1988;15:83–87
  16. Choi NC , Kanarek DJ , Grillo HC . Effect of postoperative radiotherapy on changes in pulmonary function in patients with stage II and IIIA lung carcinoma . Int J Radiat Oncol Biol Phys . 1990;18:95–99
  17. Choi NC , Kanarek DJ . Toxicity of thoracic radiotherapy on pulmonary function in lung cancer . Lung Cancer . 1994;10:S219–S230
  18. Abratt RP , Willcox PA . The effect of irradiation on lung function and perfusion in patients with lung cancer . Int J Radiat Oncol Biol Phys . 1995;31:915–919
  19. Robert F , Childs HA , Spencer SA , et al.   Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer (Analysis of early and late pulmonary morbidity) . Semin Radiat Oncol . 1999;9:136–147
  20. Sunyach MP , Falchero L , Pommier P , et al.   Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer (Preliminary results) . Int J Radiat Oncol Biol Phys . 2000;48:459–463
  21. Allen AM , Henning GT , Ten Haken RK , et al.   Do dose-volume metrics predict pulmonary function changes in lung irradiation? . Int J Radiat Oncol Biol Phys . 2003;55:921–929
  22. De Jaeger K , Seppenwoolde Y , Boersma LJ , et al.   Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;55:1331–1340
  23. Gopal R , Starkschall G , Tucker SL , et al.   Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:114–120
  24. Miller KL , Zhou SM , Barrier RC , et al.   Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:611–615
  25. Gopal R , Tucker SL , Komaki R , et al.   The relationship between local dose and loss of function for irradiated lung . Int J Radiat Oncol Biol Phys . 2003;56:106–113
  26. Brooks BJ , Seifter EJ , Walsh TE , et al.   Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer . J Clin Oncol . 1986;4:200–209
  27. Schaake-Koning C , van den Bogaert W , Dalesio O , et al.   Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer . N Engl J Med . 1992;326:524–530
  28. Jeremic B , Shibamoto Y , Acimovic L , et al.   Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer (A randomized study) . J Clin Oncol . 1996;14:1065–1070
  29. Lee JS , Scott C , Komaki R , et al.   Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer (Radiation Therapy Oncology Group protocol 91–06) . J Clin Oncol . 1996;14:1055–1064
  30. Byhardt RW , Scott C , Sause WT , et al.   Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung . Int J Radiat Oncol Biol Phys . 1998;42:469–478
  31. Monson JM , Stark P , Reilly JJ , et al.   Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma . Cancer . 1998;82:842–850
  32. Yamada M , Kudoh S , Hirata K , et al.   Risk factors of pneumonitis following chemoradiotherapy for lung cancer . Eur J Cancer . 1998;34:71–75
  33. Quon H , Shepherd FA , Payne DG , et al.   The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer . Int J Radiat Oncol Biol Phys . 1999;43:39–45
  34. Robnett TJ , Machtay M , Vines EF , et al.   Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer . Int J Radiat Oncol Biol Phys . 2000;48:89–94
  35. Hernando ML , Marks LB , Bentel GC , et al.   Radiation-induced pulmonary toxicity (A dose-volume histogram analysis in 201 patients with lung cancer) . Int J Radiat Oncol Biol Phys . 2001;51:650–659
  36. Rancati T , Ceresoli GL , Gagliardi G , et al.   Factors predicting radiation pneumonitis in lung cancer patients (A retrospective study) . Radiother Oncol . 2003;67:275–283
  37. Claude L , Perol D , Ginestet C , et al.   A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer (Clinical and dosimetric factors analysis) . Radiother Oncol . 2004;71:175–181
  38. Schild SE , Stella PJ , Geyer SM , et al.   The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly . J Clin Oncol . 2003;21:3201–3206
  39. Johansson S , Bjermer L , Franzen L , et al.   Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients . Radiother Oncol . 1998;49:41–47
  40. van Putten JW , Price A , van der Leest AH , et al.   A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer . Clin Cancer Res . 2003;9:2472–2477
  41. Blackstock AW , Lesser GJ , Fletcher-Steede J , et al.   Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2001;51:1281–1289
  42. Onishi H , Kuriyama K , Yamaguchi M , et al.   Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer (A good local response but no good survival due to radiation pneumonitis) . Lung Cancer . 2003;40:79–84
  43. Dincbas FO , Atalar B , Koca S . Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma (No good survival due to radiation pneumonitis) . Lung Cancer . 2004;43:241–242
  44. Seppenwoolde Y , De Jaeger K , Lebesque JV , et al.   Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:1208–1209 In regard to Tsujino; (IJROBP 2003;55:110–115); author reply 1209
  45. Armstrong JG , Zelefsky MJ , Leibel SA , et al.   Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer . Ann Oncol . 1995;6:693–697
  46. Graham MV , Purdy JA , Emami B , et al.   Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) . Int J Radiat Oncol Biol Phys . 1999;45:323–329
  47. Jenkins P , D’Amico K , Benstead K , et al.   Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART) . Int J Radiat Oncol Biol Phys . 2003;56:360–366
  48. Tsujino K , Hirota S , Endo M , et al.   Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer . Int J Radiat Oncol Biol Phys . 2003;55:110–115
  49. Kwa SL , Lebesque JV , Theuws JC , et al.   Radiation pneumonitis as a function of mean lung dose (An analysis of pooled data of 540 patients) . Int J Radiat Oncol Biol Phys . 1998;42:1–9
  50. Oetzel D , Schraube P , Hensley F , et al.   Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis . Int J Radiat Oncol Biol Phys . 1995;33:455–460
  51. Yorke ED , Jackson A , Rosenzweig KE , et al.   Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy . Int J Radiat Oncol Biol Phys . 2002;54:329–339
  52. Lyman JT , Wolbarst AB . Optimization of radiation therapy, III (A method of assessing complication probabilities from dose-volume histograms) . Int J Radiat Oncol Biol Phys . 1987;13:103–109
  53. Kutcher GJ , Burman C . Calculation of complication probability factors for non-uniform normal tissue irradiation (The effective volume method) . Int J Radiat Oncol Biol Phys . 1989;16:1623–1630
  54. Martel MK , Ten Haken RK , Hazuka MB , et al.   Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis . Int J Radiat Oncol Biol Phys . 1994;28:575–581
  55. Lee SW , Choi EK , Lee JS , et al.   Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:996–1004
  56. Burman C , Kutcher GJ , Emami B , et al.   Fitting of normal tissue tolerance data to an analytic function . Int J Radiat Oncol Biol Phys . 1991;21:123–135
  57. Marks LB , Munley MT , Bentel GC , et al.   Physical and biological predictors of changes in whole-lung function following thoracic irradiation . Int J Radiat Oncol Biol Phys . 1997;39:563–570
  58. Niemierko A , Goitein M . Modeling of normal tissue response to radiation (The critical volume model) . Int J Radiat Oncol Biol Phys . 1993;25:135–145
  59. Yorke ED , Kutcher GJ , Jackson A , et al.   Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation . Radiother Oncol . 1993;26:226–237
  60. Seppenwoolde Y , Engelsman M , De Jaeger K , et al.   Optimizing radiation treatment plans for lung cancer using lung perfusion information . Radiother Oncol . 2002;63:165–177
  61. Seppenwoolde Y , Lebesque JV , de Jaeger K , et al.   Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability . Int J Radiat Oncol Biol Phys . 2003;55:724–735
  62. De Jaeger K , Hoogeman MS , Engelsman M , et al.   Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer (Re-evaluation of dose in normal lung tissue) . Radiother Oncol . 2003;69:1–10
  63. Kwa SL , Theuws JC , Wagenaar A , et al.   Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis . Radiother Oncol . 1998;48:61–69
  64. Rodrigues G , Lock M , D’Souza D , et al.   Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer—a systematic review . Radiother Oncol . 2004;71:127–138
  65. Willner J , Jost A , Baier K , et al.   A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy . Strahlenther Onkol . 2003;179:548–556
  66. Hope AJ , El Naqa I , Bradley JD , et al.   Radiation pneumonitis/fibrosis risk based on dosimetric, clinical, and location-related factors . [Abstract] Int J Radiat Oncol Biol Phys . 2004;60:S204
  67. Rubin P , Johnston CJ , Williams JP , et al.   A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis . Int J Radiat Oncol Biol Phys . 1995;33:99–109
  68. Chen Y , Williams J , Ding I , et al.   Radiation pneumonitis and early circulatory cytokine markers . Semin Radiat Oncol . 2002;12:26–33
  69. Chen Y , Rubin P , Williams J , et al.   Circulating IL-6 as a predictor of radiation pneumonitis . Int J Radiat Oncol Biol Phys . 2001;49:641–648
  70. Ishii Y , Kitamura S . Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis . Eur Respir J . 1999;13:733–738
  71. Sasaki R , Soejima T , Matsumoto A , et al.   Clinical significance of serum pulmonary surfactant proteins A and D for the early detection of radiation pneumonitis . Int J Radiat Oncol Biol Phys . 2001;50:301–307
  72. Goto K , Kodama T , Sekine I , et al.   Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis . Lung Cancer . 2001;34:141–148
  73. Hara R , Itami J , Komiyama T , et al.   Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors . Chest . 2004;125:340–344
  74. Fujita J , Ohtsuki Y , Bandoh S , et al.   Elevation of cytokeratin 19 fragment (CYFRA 21–1) in serum of patients with radiation pneumonitis (Possible marker of epithelial cell damage) . Respir Med . 2004;98:294–300
  75. Koizumi M , Yamazaki H , Toyokawa K , et al.   Influence of thoracic radiotherapy on exhaled nitric oxide levels in patients with lung cancer . Jpn J Clin Oncol . 2001;31:142–146
  76. Hauer-Jensen M , Kong FM , Fink LM , et al.   Circulating thrombomodulin during radiation therapy of lung cancer . Radiat Oncol Investig . 1999;7:238–242
  77. Vujaskovic Z , Groen HJ . TGF-beta, radiation-induced pulmonary injury and lung cancer . Int J Radiat Biol . 2000;76:511–516
  78. Anscher MS , Kong FM , Andrews K , et al.   Plasma transforming growth factor β1 as a predictor of radiation pneumonitis . Int J Radiat Oncol Biol Phys . 1998;41:1029–1035
  79. Barthelemy-Brichant N , Bosquee L , Cataldo D , et al.   Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy . Int J Radiat Oncol Biol Phys . 2004;58:758–767
  80. Fu XL , Huang H , Bentel G , et al.   Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor β . Int J Radiat Oncol Biol Phys . 2001;50:899–908
  81. De Jaeger K , Seppenwoolde Y , Kampinga HH , et al.   Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2004;58:1378–1387
  82. Novakova-Jiresova A , Van Gameren MM , Coppes RP , et al.   Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients . Radiother Oncol . 2004;71:183–189
  83. Bentzen SM , Saunders MI , Dische S . From CHART to CHARTWEL in non-small cell lung cancer (Clinical radiobiological modelling of the expected change in outcome) . Clin Oncol (R Coll Radiol) . 2002;14:372–381
  84. Chen GY , Jiang GL , Qian H , et al.   Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer (A clinical phase II trial) . Radiother Oncol . 2004;71:157–162
  85. Saunders M , Dische S , Barrett A , et al.  CHART Steering Committee   Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer (A randomised multicentre trial) . Lancet . 1997;350:161–165
  86. Kirkbride P , Hatton M , Lorigan P , et al.   Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer . Clin Oncol (R Coll Radiol) . 2002;14:361–366
  87. Oral EN , Bavbek S , Kizir A , et al.   Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer . Lung Cancer . 1999;25:191–198
  88. Saunders MI , Rojas A , Lyn BE , et al.   Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer . Clin Oncol (R Coll Radiol) . 2002;14:352–360
  89. Rosenman JG , Halle JS , Socinski MA , et al.   High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer (Technical issues and results of a phase I/II trial) . Int J Radiat Oncol Biol Phys . 2002;54:348–356
  90. Narayan S , Henning GT , Ten Haken RK , et al.   Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer . Lung Cancer . 2004;44:79–88
  91. Wu KL , Jiang GL , Liao Y , et al.   Three-dimensional conformal radiation therapy for non-small-cell lung cancer (A phase I/II dose escalation clinical trial) . Int J Radiat Oncol Biol Phys . 2003;57:1336–1344
  92. Hayman JA , Martel MK , Ten Haken RK , et al.   Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy (Update of a phase I trial) . J Clin Oncol . 2001;19:127–136
  93. Bhatnagar A , Flickinger JC , Bahri S , et al.   Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams . Clin Lung Cancer . 2002;3:259–264
  94. Koenig TR , Munden RF , Erasmus JJ , et al.   Radiation injury of the lung after three-dimensional conformal radiation therapy . AJR Am J Roentgenol . 2002;178:1383–1388
  95. Wurstbauer K , Deutschmann H , Sedlmayer F , et al.   Non-small-cell lung cancer (Dose escalation by target splitting with asymmetric collimation) . Clin Lung Cancer . 2001;3:151–153
  96. Dirkx ML , Essers M , van Sornsen de Koste JR , et al.   Beam intensity modulation for penumbra enhancement in the treatment of lung cancer . Int J Radiat Oncol Biol Phys . 1999;44:449–454
  97. Dirkx ML , Heijmen BJ . Beam intensity modulation for penumbra enhancement and field length reduction in lung cancer treatments (A dosimetric study) . Radiother Oncol . 2000;56:181–188
  98. van Sornsen de Koste J , Voet P , Dirkx M , et al.   An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer . Lung Cancer . 2001;32:145–153
  99. Murshed H , Liu HH , Liao Z , et al.   Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2004;58:1258–1267
  100. Mackie TR , Balog J , Ruchala K , et al.   Tomotherapy . Semin Radiat Oncol . 1999;9:108–117
  101. Scrimger RA , Tome WA , Olivera GH , et al.   Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements . Am J Clin Oncol . 2003;26:70–78
  102. Sun LM , Leung SW , Wang CJ , et al.   Concomitant boost radiation therapy for inoperable non-small-cell lung cancer (Preliminary report of a prospective randomized study) . Int J Radiat Oncol Biol Phys . 2000;47:413–418
  103. Pottgen C , Eberhardt W , Bildat S , et al.   Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb) (A pilot phase I/II trial) . Ann Oncol . 2002;13:403–411
  104. Hof H , Herfarth KK , Munter M , et al.   Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC) . Int J Radiat Oncol Biol Phys . 2003;56:335–341
  105. Lee SW , Choi EK , Park HJ , et al.   Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung . Lung Cancer . 2003;40:309–315
  106. Suit H . The Gray Lecture 2001 (Coming technical advances in radiation oncology) . Int J Radiat Oncol Biol Phys . 2002;53:798–809
  107. Bonnet RB , Bush D , Cheek GA , et al.   Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer . Chest . 2001;120:1803–1810
  108. Satoh H , Okumura T , Yamashita YT , et al.   Proton irradiation for non-small cell lung cancer . Arch Intern Med . 1998;158:1379–1380
  109. Shioyama Y , Tokuuye K , Okumura T , et al.   Clinical evaluation of proton radiotherapy for non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:7–13
  110. Miyamoto T , Yamamoto N , Nishimura H , et al.   Carbon ion radiotherapy for stage I non-small cell lung cancer . Radiother Oncol . 2003;66:127–140
  111. Kadono K , Homma T , Kamahara K , et al.   Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients . Chest . 2002;122:1925–1932
  112. Jeremic B , Shibamoto Y , Milicic B , et al.   Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone . Lung Cancer . 2003;40:317–323
  113. Rosenzweig KE , Mychalczak B , Fuks Z , et al.   Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer . Cancer J . 2000;6:82–87
  114. Yorke ED , Wang L , Rosenzweig KE , et al.   Evaluation of deep inspiration breath-hold lung treatment plans with Monte Carlo dose calculation . Int J Radiat Oncol Biol Phys . 2002;53:1058–1070
  115. Rosenzweig KE , Hanley J , Mah D , et al.   The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2000;48:81–87
  116. Kwok E , Chan CK . Corticosteroids and azathioprine do not prevent radiation-induced lung injury . Can Respir J . 1998;5:211–214
  117. Antonadou D , Coliarakis N , Synodinou M , et al.   Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer . Int J Radiat Oncol Biol Phys . 2001;51:915–922
  118. Antonadou D , Throuvalas N , Petridis A , et al.   Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;57:402–408
  119. Komaki R , Lee JS , Milas L , et al.   Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer (Report of a randomized comparative trial) . Int J Radiat Oncol Biol Phys . 2004;58:1369–1377
  120. Werner-Wasik M , Scott C , Movsas B , et al.   Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT) (Results of the Radiation Therapy Oncology Group (RTOG) 98–01 study) . Int J Radiat Oncol Biol Phys . 2003;57:S216
  121. Ward WF , Lin PJ , Wong PS , et al.   Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography . Radiat Res . 1993;135:81–87
  122. Wang LW , Fu XL , Clough R , et al.   Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? . Radiat Res . 2000;153:405–410
  123. Molteni A , Moulder JE , Cohen EF , et al.   Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker . Int J Radiat Biol . 2000;76:523–532
  124. Ozturk B , Egehan I , Atavci S , et al.   Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer (A double-blind randomized trial) . Int J Radiat Oncol Biol Phys . 2004;58:213–219
  125. Vijayalaxmi  , Reiter RJ , Tan DX , et al.   Melatonin as a radioprotective agent (A review) . Int J Radiat Oncol Biol Phys . 2004;59:639–653
  126. Jonsson OE , Bjermer L , Denekamp J , et al.   Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation . Eur J Cancer . 1999;35:1268–1273
  127. Guo H , Epperly MW , Bernarding M , et al.   Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas . In Vivo . 2003;17:13–21

 Supported by a grant from MedImmune Oncology, Inc. The author receives research support, has served on the speaker’s bureau, and has served as a consultant for MedImmune Oncology, Inc.

PII: S0360-3016(05)00582-1

doi: 10.1016/j.ijrobp.2005.03.047

International Journal of Radiation Oncology * Biology * Physics
Volume 63, Issue 1 , Pages 5-24 , 1 September 2005

Article Tools

* Image Usage & Resolution